multipl opportun upsid
pt
buy thesi remain in-tact strong healthi guidanc leav
room upsid core growth guidanc in-lin consensu
ep guidanc midpoint adjust recent divestitur see room
strong trend continu remain bit guidanc organ growth
tenet bullish view evid robust biopharma
growth continu outsiz strength china solid execut capit
alloc option anoth key posit factor spend
buyback ytd factor addit buyback model
could materi accret see impact/accret analysi
quick take quarter
standout biopharma growth low-teen ub estimate china
grew though industrial/appli growth also impress
academic/govt grew year stack comp growth best
year margin lp sd segment miss cite mix invest
expect bp expans absorb bp tariff
divestitur remain optimist margin outlook
strength china pharma industri read across well peer solid industri
big surpris guidanc incorpor bit slower growth l-
msd growth europ vs mid-teen growth china still
robust compar guidanc hsd pharma growth
stabl stack around beg
question tough comp matter robust trend key area
bioproduct bioscienc clinic trial logist share gain lead anoth year
valuat pt
dcf incorpor wacc perpetu growth rate rais
pt account gener sinc first set target
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price jan estimate
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
million us except per share amount
good
interest expens incom
net incom continu op
million us except per share amount
good
interest expens incom
net incom continu op
valuat method risk statement
discount cash flow primari valuat method dcf incorpor
wacc lt growth assumpt
industry-wid risk includ declin spend pharmaceut compani
due signific declin fund small compani promin
trial failur affect class drug deceler global growth
includ risk escal trade tension pressur academ
govern budget could result recessionari cost-cut
polit chang price pressur diagnost sector due
protect access medicar act pama chang competit dynam
includ disrupt new entrant certain technolog inabl
compani compet effect china critic growth market foreign
exchang fluctuat chang tax polici
risk
includ biopharma slow chines economi
integr recent larg make bad strateg decis futur
